Carlsquare advised the shareholders of kalmeda (mynoise GmbH) on the sale to Pohl-Boskamp
Kalmeda manufacturer mynoise GmbH was founded in 2015 by ENT physician Dr. Uso Walter to develop a therapy for tinnitus patients. Kalmeda is the first and only fully approved behavioural therapy for chronic tinnitus with class 1 evidence. Developed by psychologists and ENT physicians, the app provides a clinically proven 24/7 tool for symptom reduction. Through the classification, the app-based therapy can be prescribed directly by the treating physician or psychotherapist and the associated costs are covered by the patient’s health insurance.
G. Pohl-Boskamp, headquartered in Hohenlockstedt, Schleswig-Holstein, is a medium-sized pharmaceutical company. Owner Marianne Boskamp manages the family-run company in the fourth generation together with her husband Dr. Henning Ueck. Pohl-Boskamp’s portfolio includes pharmaceuticals and medical products, for example branded products such as GeloMyrtol forte, GeloRevoice, Nyda, Loyon and Gepan.
“We would like to thank Carlsquare for successfully advising us on the sale of mynoise GmbH (kalmeda) to Pohl Boskamp. Carlsquare’s expertise and strategic insights were invaluable throughout the process and ensured a smooth and fruitful transaction. We look forward to the next stage in the company’s development and to the synergies that will result from this partnership in the future.” – Christof Schifferings, CEO mynoise GmbH
Carlsquare acted as the exclusive financial advisor to kalmeda.